Neurexis Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $3M

  • Investors
  • 4

Neurexis Therapeutics General Information

Description

Developer of therapeutic peptides designed to significantly reduce brain damage from stroke. The company's tool provides an improved peptide with demonstrated efficacy, consisting of two functional domains for the drug to cross the blood-brain barrier, enabling patients to get a neuroprotective option for stroke that would lessen brain damage and long-term health impacts.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bioscience 1, 12635 East Montview Boulevard
  • Suite 100
  • Aurora, CO 80045
  • United States
+1 (720)
Primary Industry
Biotechnology
Corporate Office
  • Bioscience 1, 12635 East Montview Boulevard
  • Suite 100
  • Aurora, CO 80045
  • United States
+1 (720)

Neurexis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurexis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 18-Sep-2024 $3M Completed Pre-Clinical Trials
6. Grant 19-Apr-2023 Completed Pre-Clinical Trials
5. Early Stage VC 23-May-2022 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 07-Mar-2022 Cancelled Pre-Clinical Trials
3. Grant 13-Oct-2021 Completed Pre-Clinical Trials
2. Seed Round 26-Apr-2021 $500K $500K Completed Pre-Clinical Trials
1. Grant 02-Jun-2020 $250K Completed Startup
To view Neurexis Therapeutics’s complete valuation and funding history, request access »

Neurexis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Neurexis Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neurexis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurexis Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
National Institutes of Neurological Disorders and Stroke Government
VIC Technology Venture Development Venture Capital Minority
Colorado Venture Capital Authority Government
To view Neurexis Therapeutics’s complete investors history, request access »

Neurexis Therapeutics FAQs

  • When was Neurexis Therapeutics founded?

    Neurexis Therapeutics was founded in 2020.

  • Where is Neurexis Therapeutics headquartered?

    Neurexis Therapeutics is headquartered in Aurora, CO.

  • What is the size of Neurexis Therapeutics?

    Neurexis Therapeutics has 4 total employees.

  • What industry is Neurexis Therapeutics in?

    Neurexis Therapeutics’s primary industry is Biotechnology.

  • Is Neurexis Therapeutics a private or public company?

    Neurexis Therapeutics is a Private company.

  • What is Neurexis Therapeutics’s current revenue?

    The current revenue for Neurexis Therapeutics is .

  • How much funding has Neurexis Therapeutics raised over time?

    Neurexis Therapeutics has raised $555K.

  • Who are Neurexis Therapeutics’s investors?

    National Institutes of Health, National Institutes of Neurological Disorders and Stroke, VIC Technology Venture Development, and Colorado Venture Capital Authority have invested in Neurexis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process